| DIRECT COMPETITOR COMPARISON | |
| CRME | ARYX | NBIX | Pvt1 | Industry | | Market Cap: | 241.86M | 74.76M | 82.72M | N/A | 161.24M | | Employees: | 104 | 75 | 125 | N/A | 103 | | Qtrly Rev Growth (yoy): | 3,830.80% | N/A | -3.70% | N/A | 20.50% | | Revenue (ttm): | 28.55M | N/A | 2.94M | N/A | 46.74M | | Gross Margin (ttm): | -10.53% | N/A | N/A | N/A | 68.58% | | EBITDA (ttm): | -19.57M | -37.36M | -47.02M | N/A | -7.12M | | Oper Margins (ttm): | -80.54% | N/A | -1,740.48% | N/A | 2.25% | | Net Income (ttm): | -20.94M | -40.43M | -71.98M | N/A | N/A | | EPS (ttm): | -0.328 | -1.539 | -1.853 | N/A | -0.17 | | P/E (ttm): | N/A | N/A | N/A | N/A | 17.12 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.04 | | P/S (ttm): | 8.47 | N/A | 28.12 | N/A | 4.17 |
|
| ARYX = ARYx Therapeutics, Inc. | | NBIX = Neurocrine Biosciences Inc. | | Pvt1 = Scios Inc. (privately held) | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | 0.00% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | 0.00% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | 0.00% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | 0.00% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | 0.00% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | 0.00% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | 0.00% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | 0.00% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | 0.00% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | 0.00% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | 0.00% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | 0.00% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | 0.00% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | 0.00% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | 0.00% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | 0.00% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | 0.00% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | NBIX | | Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
Tue, Nov 24 -
PR Newswire | | • | ARYX | | ARYX THERAPEUTICS, INC. Financials
Wed, Nov 18 -
EDGAR Online Financials | | • | ARYX | | Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association
Wed, Nov 18 -
Business Wire | | • | ARYX | | New Star Analyst Rankings for ARYx Therapeutics, Inc.
Sun, Nov 15 -
StarMine | | • | ARYX | | ARYX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Fri, Nov 13 -
EDGAR Online | | • | ARYX | | Aryx Therapeutics reports $8.2M loss
Thu, Nov 12 -
at bizjournals.com | | • | NBIX | | NEUROCRINE BIOSCIENCES INC Financials
Wed, Nov 4 -
EDGAR Online Financials | | • | NBIX | | NEUROCRINE BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report
Thu, Oct 29 -
EDGAR Online | | • | NBIX | | Neurocrine Biosciences, Inc. Q3 2009 Earnings Conference Call
Thu, Oct 29 -
at Seeking Alpha | | • | NBIX | | NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
Wed, Oct 28 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 0.00%
Competitors
